SCHEMBL448200

SCHEMBL448200

N#Cc1cc[c]o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16288966 0.70
SCHEMBL769225 0.61
SCHEMBL11196353 0.61
SCHEMBL3035808 0.57
SCHEMBL18631497 0.56 CHRM2 (0.48)
SCHEMBL4756493 0.55
SCHEMBL855237 0.55
SCHEMBL1483671 0.54
SCHEMBL449090 0.54
SCHEMBL9621966 0.54

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117062815-A VMAT2 inhibitors and methods of use 纽罗克里生物科学有限公司 2023-11-14 CN claimed
EP-4168409-A1 VMAT2 INHIBITORS AND METHODS OF USE Neurocrine Biosciences, Inc. (US) 2023-04-26 EP claimed
CN-110590708-B Aroyl piperazine compound, preparation method thereof and application thereof in antivirus 中国医学科学院医药生物技术研究所 2021-08-17 CN claimed
US-9233961-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2016-01-12 US claimed
US-20140275013-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2014-09-18 US claimed
US-20140221354-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY EMBLEM TECHNOLOGY TRANSFER GMBH (DE) 2014-08-07 US claimed
EP-2691392-A1 IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY EMBLEM Technology Transfer GmbH (DE) 2014-02-05 EP claimed
WO-2012130306-A1 BICYCLIC 2,3-DIHYRDOBENZAZINE COMPOUNDS FOR USE IN THERAPY ELARA PHARMACEUTICALS GMBH (DE) 2012-10-04 WO claimed
WO-2012130322-A1 IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY ELARA PHARMACEUTICALS GMBH (DE) 2012-10-04 WO claimed
WO-2011057892-A1 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES ELARA PHARMACEUTICALS GMBH (DE) 2011-05-19 WO claimed
EP-1222184-B1 PREPARATION AND USE OF GAMMA-BUTYROLACTONES AS CROSS-LINKING AGENTS DU PONT (US) 2006-11-02 EP claimed
US-20240010647-A1 SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS NEUROCRINE BIOSCIENCES, INC. 2024-01-11 US disclosed
CN-117062815-A VMAT2 inhibitors and methods of use 纽罗克里生物科学有限公司 2023-11-14 CN disclosed
US-11718618-B2 Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors NEUROCRINE BIOSCIENCES, INC. (US) 2023-08-08 US disclosed
US-20230159528-A1 VMAT2 INHIBITORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-05-25 US disclosed
US-6423850-B1 CROSSLINKING COATINGS E.I. DU PONT DE NEMOURS AND COMPANY 2002-07-23 US disclosed
EP-0555153-A1 Pyrethrinoide esters, derivatives of furan- or thiophenalcohol, process for their preparation and application thereof as pesticides ROUSSEL UCLAF (FR) 1993-08-11 EP disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 US disclosed
EP-0318860-B1 SUBSTITUTED ALKYLAMINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-06-16 EP disclosed
EP-0318860-A2 Substituted alkylamine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-06-07 EP disclosed